Medical Xpress
Researchers use new machine learning method to detect self-harm history hidden in veterans' medical records
Researchers have developed a machine learning tool capable of surfacing self-harm history buried in veterans' unstructured medical records — information routinely missed by standard diagnostic code searches. The method addresses a critical gap in mental health surveillance, where reliance on billing codes alone leaves significant clinical history invisible. For a population at elevated suicide risk, more complete data could meaningfully improve both individual care and broader prevention efforts.
Read article →
Stat News
Opinion: American horses are obese, too
American horses are increasingly suffering from obesity-related health conditions that mirror the chronic disease patterns seen in humans. Veterinarians and researchers are pointing to sedentary lifestyles, calorie-dense feed, and overindulgent owners as key culprits. The trend raises uncomfortable questions about how human habits and cultural attitudes toward food extend even to the animals in our care.
Read article →Medical Xpress
Trial to test AI for prostate MRI cancer diagnosis
A UCL-led international trial is set to rigorously test whether artificial intelligence can match expert radiologists in detecting prostate cancer through MRI scans. The study addresses a critical bottleneck in diagnostics, where a global shortage of specialist radiologists delays life-saving cancer identification. If validated, AI-assisted analysis could dramatically expand access to fast, accurate prostate cancer screening worldwide.
Read article →
Stat News
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim's obesity candidate delivered strong results on liver fat reduction, but underwhelming weight loss performance compared to rivals raises questions about its competitive edge in an increasingly crowded market. The new data could complicate the German drugmaker's pitch to carve out meaningful market share against entrenched players like Novo Nordisk and Eli Lilly. For a class of drugs where pounds lost remains the headline metric, falling short on that front is a difficult story to spin.
Read article →
Stat News
STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
The American Diabetes Association's annual conference delivered a packed slate of developments, with mounting competition in the obesity drug space emerging as a central theme. Clinical blind spots in diabetes care also drew significant attention, highlighting gaps that could affect how patients are diagnosed and treated. The findings underscore how rapidly the metabolic disease landscape is evolving — and how much ground the field still has to cover.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →